Receive The Newest Study Notifications

Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication

by Lance Smith | Jan 8, 2020 | Study Scavenger Clinical Trial Recruitment Platform

– Evaluates avasopasem manganese’s ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer — — Marks expansion of lead product candidate avasopasem manganese into second radiation toxicity indication —...

Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer

by Lance Smith | Jan 8, 2020 | Study Scavenger Clinical Trial Recruitment Platform

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that the...

Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

by Lance Smith | Jan 7, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Phase 3 KEYNOTE-604 Study Did Not Meet Other Dual Primary Endpoint of Overall Survival; Results to be Presented at Upcoming Medical Meeting KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...

Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in SchizophreniaTop-line results expected in the second quarter of 2020

by Lance Smith | Jan 7, 2020 | Study Scavenger Clinical Trial Recruitment Platform

WALTHAM, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc.(NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of central nervous system (CNS)...

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

by Lance Smith | Jan 7, 2020 | Study Scavenger Clinical Trial Recruitment Platform

NEWARK, Calif., Jan. 6, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been initiated. Hereditary hemochromatosis is a...

Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

by Lance Smith | Jan 7, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Company Continues to Expect Top-line Data in First Half of 2020 REDWOOD CITY, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for...